tbuckley/cabot-search huggingface dataset:
Genome-Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome After Azacitidine Treatment.
Authors: Hyang-Min Byun, Timothy Triche, Hyeoung-Joon Kim, Hee Nam Kim, Yeo-Kyeoung Kim, Il-Kwon Lee, Jae-Sook Ahn, Je-Jung Lee, Deok-Hwan Yang, Hoon Kook, Tai Ju Hwang, Peter W. Laird, Daniel Weisenberger, Allen S. Yang
Journal: Blood (2009)
Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute
Authors: Ian W. Flinn, Dana S. Thompson, Ralph V. Boccia, Gerald Miletello, Andrew Lipman, Douglas Flora, Daniel Cuevas, Steven W. Papish, Jesus G. Berdeja
Journal: Blood (2012)
Low Counts of Plasmacytoid Dendritic Cells After Engraftment Are Associated with Higher Early Transplantation-Related Mortality in Patients Receiving Unrelated HSCT
Authors: Matheus Vescovi GonÇalves, Mihoko Yamamoto, Vergílio Antônio Rensi Colturato, Mair Pedro de Souza, Marcos Mauad, Maura Valerio Ikoma, Eliza Y. S. Kimura, Fabio P. Guirao, Nelson Hamerschlak, Fabio R. Kerbauy, Leonardo Raul Morelli, Yana Novis, valeria Cortez Ginani, Adriana Seber, Vanderson Rocha, Alberto Orfao, Celso Arrais Rodrigues
Journal: Blood (2011)
Genetic Analyses in the Uganda Sickle Surveillance Study: Modifiers of Sickle Cell Anemia and Identification of Hemoglobin Variants
Authors: Beverly A Schaefer, Charles Kiyaga, Thad A. Howard, Grace Ndeezi, Arielle G Hernandez, Isaac Ssewanyana, Mary C. Paniagua, Christopher Ndugwa, Jane Aceng, Russell E. Ware
Journal: Blood (2016)
International Prognostic Scoring System (IPSS) for Waldenström’s Macroglobulinemia (WM).
Authors: Pierre Morel, Alain Duhamel, Paolo Gobbi, Meletios Dimopoulos, Madhav Dhodapkar, Jason McCoy, Enrique Ocio, Ramon Garcia-Sanz, Steven Treon, Veronique Leblond, Robert Kyle, Bart Barlogie, Giampaolo Merlini
Journal: Blood (2006)
Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus “7+3” for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML)
Authors: Joshua F. Zeidner, Jonathan M. Gerber, Amanda Blackford, Mark Litzow, Matthew C. Foster, Lawrence E. Morris, Ivana Gojo, Jeffrey E. Lancet, Prithviraj Bose, Raoul Tibes, Stephen A. Strickland, Jacqueline M Greer, Michelle Drye, Kevin Meads, Austin Doyle, Richard F Little, John J Wright, Judith E. Karp
Journal: Blood (2012)
Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML).
Authors: Roberto Latagliata, Massimo Breccia, Simona Iacobelli, Paola Fazi, Giovanni Martinelli, Francesco Di Raimondo, Marco Sborgia, Francesco Fabbiano, Francesco Lauria, Eliana Zuffa, Adriano Venditti, Monica Crugnola, Antonio Peta, Anna Candoni, Daniela Cilloni, Enrico Mattei, Monica Morselli, Domenico Pastore, Francesca Adamo, Antonia Centra, Franca Falzetti, Marco Vignetti, Giuliana Alimena, Franco Mandelli
Journal: Blood (2006)
High Thrombin Generation Measured In the Presence of Activated Protein C Is Associated with An Increased Risk of Recurrence Among Women 18–64 Years After a First Event of VTE
Authors: Kristina Sonnevi, Svetlana N Tchaikovski, Katarina Bremme, Margareta Holmstrom, Jan Rosing, Gerd Larfars
Journal: Blood (2010)
Flow Cytometry Is Highly Predictive In Excluding Myelodysplastic Syndromes In Patients With Indeterminable Cytopenia: A Prospective Analysis Of 316 Patients
Authors: Eline M.P. Cremers, Theresia M Westers, Canan Alhan, Marielle J. Wondergem, Pino J. Poddighe, Claudia Cali, C.W.M. Schouten, Gert J. Ossenkoppele, Arjan A. Van de Loosdrecht
Journal: Blood (2013)
Impact of fluoropyrimidine switching in sequential treatment of first- and second-line n unresectable colorectal cancer
Authors: Yusuke Nagata, Ryoichi Sawada, Kentaro Harada, Hayato Mikuni, Masashi Ishikawa, Tomohiro Kano, Utako Ishimoto, Takashi Nishimura, Masaaki Noguchi, Masahisa Ohkuma, Eijiro Nagasaki, Katsushi Amano, Ken Eto, Katsuhiko Yanaga, Masayuki Saruta
Journal: Annals of Oncology (2019)
A Unique Recombinant Plasmin Molecule Lacking Kringles 2-5 Possesses Equivalent Hemostatic Safety as Full-Length Human Plasmin.
Authors: Victor J. Marder, Valery Novokhatny, Steve Manyak, Theresa Gruber, Jennifer Hunt, John Bromirski, Abha Goyal, Philip Scuderi, Steve Petteway
Journal: Blood (2008)
Angiopoietin-2 Expression in B-Cell Chronic Lymphocytic Leukemia: Association with Clinical Outcome and Immunoglobulin Heavy-Chain Mutational Status.
Authors: Rossana Maffei, Silvia Martinelli, Ilaria Castelli, Rita Santachiara, Elena Morandi, Patrizia Zucchini, Marcella Fontana, Anna Maria Colacci, Roberto Serra, Roberto Marasca, Giuseppe Torelli
Journal: Blood (2006)
A profile of arginine methyltransferase receptors in two immortal glioblastoma cell lines: the precursor to a novel target?
Authors: Srihari Deepak, Miss Sabrina Samuel, John Greenman, Shailendra Achawal, Pedro Beltran-Alvarez
Journal: Neuro-Oncology (2019)

Abstract Background Glioblastoma is a deadly disease with a median survival of 15 months after treatment. While maximal safe surgical resection and adjuvant chemoradiotherapy continues to be the mainstay of treatment, glioblastoma demostrates a remarkably heterogeneous molecular profile, and there is a drive to discover further chemotherapeutic targets that can effectively augment current multimodal therapy. Introduction Post-translational modification of proteins plays a key role in maintenance of regulatory cell networks, and protein arginine methyltransferases (PRMT) are one of the enzymes involved in symmetric and asymmetric methylation of various proteins. We aim to demonstrate the entire range of PRMT proteins expressed in two different glioblastoma cell lines (U87MG and U251) in order to elucidate a consistency in expression of these proteins across cell lines. Methods Cells from 2 different glioblastoma cell lines (U87MG and U251) were cultured and lysed using standard aseptic techniques. Protein profiling was done using SDS-PAGE electrophoresis with a molecular weight marker as the reference and all primary antibodies to various PRMTs (1–10) and respective secondary antibodies. Membranes were visualised with a chemiluminescent protocol. Experiments were repeated in order to reduce bias. Conclusion It was clearly seen that in both cell lines there is a strong tendency for PRMT5 expression and relative under-expresssion of PRMT 9/10. In addition, however, there are varying expressions of other PRMTs as well. We aim to further explore this to improve the strength of this correlation.
Effectiveness of WT1 Peptide Vaccination Combined with Imatinib in a Patient with CML in Chronic Phase.
Authors: Anri Saitoh, Miwako Narita, Akie Yamahira, Takeshi Nakamura, Nozomi Tochiki, Norihiro Watanabe, Masami Kaji, Tomoyo Taniguchi, Masayoshi Masuko, Tatsuo Furukawa, Ken Toba, Ichiro Fuse, Yoshifusa Aizawa, Masuhiro Takahashi
Journal: Blood (2009)
Integrated In Silico Prediction of Minor Histocompatibility Antigen Peptides in HLA-Matched Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Authors: Jefferson L. Lansford, Shengjie Chai, Gheath Alatrash, Jeffrey J. Molldrem, Paul M. Armistead, Benjamin G. Vincent
Journal: Blood (2016)
Safety and Tolerability of Donor Type Red Blood Cell Transfusion before Allogeneic Stem Cell Transplantation in Children with Major ABO Mismatch
Authors: Andrea Jarisch, Jan Soerensen, Emilia Salzmann, Eva Rettinger, Andre Manfred Willasch, Shahrzad Bakhtiar, Rejane Bager, Dieter Klarmann, Thomas Klingebiel, Peter Bader
Journal: Blood (2016)
MYD88 L265P Mutation Detection: Analysis of Flow Cytometry Sorted Plasma and Lymphoid Cell Clones Improves Sensitivity and Specificity for WM/LPL Diagnosis
Authors: Zhixing Wang, Wayne Fritschle, Richard Bennington, Bettina Burnworth, Angela Bennington, Collette Wentzel, Stephanie Verkamp, Phung Nguyen, Keely Ghirardelli, Lisa Broderson, Denise A. Wells, Michael R. Loken, Barbara Katharina Zehentner
Journal: Blood (2014)
MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma
Authors: Andres E. Quesada, Parth Desai, Guilin Tang, Pei Lin, Jason R. Westin, Adam C. Seegmiller, C. Cameron Yin, Wei Wang, Jie Xu, Roberto N. Miranda, Nishitha Reddy, L. Jeffrey Medeiros, Shaoying Li
Journal: Blood (2016)
Transfusion Efficacy of Apheresis Platelet Concentrates (APCs) Irradiated in Advance Is Significantly Lower Compared to Products Irradiated within 24 hours Before Transfusion.
Authors: Friedgard Julmy, Roland A Ammann, Behrouz Mansouri Taleghani, Stefano Fontana, Andreas Hirt, Kurt Leibundgut
Journal: Blood (2009)
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA
Authors: Helen Brown, Johan Vansteenkiste, Kazuhiko Nakagawa, Manuel Cobo, Thomas John, Craig Barker, Alexander Kohlmann, Alexander Todd, Matilde Saggese, Juliann Chmielecki, Aleksandra Markovets, Marietta Scott, Suresh S. Ramalingam
Journal: Journal of Thoracic Oncology (2019)

EGFR mutated (EGFRm) NSCLC tumors occasionally express programmed cell death ligand 1 (PD-L1), although frequency and clinical relevance are not fully characterized. We report PD-L1 expression in patients with EGFRm advanced NSCLC and association with clinical outcomes following treatment with osimertinib or comparator EGFR tyrosine kinase inhibitors in the FLAURA trial (phase III, NCT02296125).Of 231 tissue blocks available from the screened population (including EGFRm-positive and -negative samples), 197 had sufficient tissue for PD-L1 testing using the SP263 (Ventana, Tucson, Arizona) immunohistochemical assay. Tumor cell (TC) staining thresholds of PD-L1 TC greater than or equal to 1%, TC greater than or equal to 25%, and TC greater than or equal to 50% were applied. Progression-free survival (PFS) was investigator-assessed, per Response Evaluation Criteria in Solid Tumor, version 1.1, according to PD-L1 expressors (TC ≥ 1%) or negatives (TC < 1%) in randomized patients.PD-L1 staining was successful in 193 of 197 patient formalin-fixed paraffin-embedded blocks; of these, 128 of 193 were EGFRm-positive and 106 of 128 patients were randomized to treatment (osimertinib: 54; comparator: 52). At the PD-L1 TC greater than or equal to 25% threshold, 8% (10 of 128) of EGFRm-positive tumors expressed PD-L1 versus 35% (23 of 65) of EGFRm-negative tumors. With the TC greater than or equal to 1% threshold, 51% (65 of 128) versus 68% (44 of 65) were mutation-positive and -negative, respectively, and with the TC greater than or equal to 50% threshold, 5% (7 of 128) versus 28% (18 of 65), were mutation-positive and -negative, respectively. For PD-L1 expressors (TC ≥ 1%), median PFS was 18.4 months with osimertinib and 6.9 months with comparator (hazard ratio = 0.30; 95% confidence interval: 0.15-0.60). For PD-L1-negative patients (TC < 1%), median PFS was 18.9 months with osimertinib and 10.9 months with comparator (hazard ratio = 0.37; 95% confidence interval: 0.17-0.74).Clinical benefit with osimertinib was unaffected by PD-L1 expression status.
BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment
Authors: Paolo Neviani, Jason G Harb, Joshua J Oaks, Christopher Walker, Ramasamy Santhanam, Carolyn Paisie, Anna Eiring, Bin Zhang, Bastianella Perazzona, Y. Ma, Charlene Mao, Guido Marcucci, Tessa L. Holyoake, Stefano Volinia, Jorge E. Cortes, Michael A. Caligiuri, Claudia Huettner, Robert Bittman, Ching-Shih Chen, Ralph B. Arlinghaus, Peter Hokland, Denis-Claude Roy, Ravi Bhatia, Danilo Perrotti
Journal: Blood (2010)
Pgk-Mediated Expression of Common Gamma Chain Is More Effective Than EF1a for Therapeutic Immune Reconstitution of X-SCID Dogs after In Vivo Gene Therapy with Foamy Virus Vector
Authors: Olivier Humbert, Christopher R Burtner, Patricia O'Donnell, Daniel R Humphrys, Nicholas Hubbard, Frieda Chan, Jennifer E Adair, Grant D. Trobridge, Troy Torgerson, Andrew M. Scharenberg, David J. Rawlings, Peter Felsburg, Hans-Peter Kiem
Journal: Blood (2015)
Low-Dose Antithymocyte Globulin, Post-Transplant Cyclophosphamide and Sirolimus As Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Transplants
Authors: Raffaella Greco, Jacopo Peccatori, Lara Crucitti, Luca Vago, Nicoletta Cieri, Fabio Giglio, Maria Teresa Lupo Stanghellini, Mara Morelli, Maria Chiara Barbanti, Simona Piemontese, Tommaso Perini, Elisa Sala, Francesca Pavesi, Carlo Messina, Raffaella Milani, Magda Marcatti, Sarah Marktel, Matteo G Carrabba, Massimo Bernardi, Consuelo Corti, Andrea Assanelli, Chiara Bonini, Fabio Ciceri
Journal: Blood (2015)
MLL genomic DNA Breakpoints In Infant Acute Leukemia
Authors: Grigory Tsaur, Claus Meyer, Alexander Popov, Olga Plekhanova, Anatoly Kustanovich, Alena Volochnik, Tatyana Riger, Anna Demina, Alexander Druy, Elena Fleischman, Olga Sokova, Yulia Olshanskaya, Olga Streneva, Egor Shorikov, Leonid Saveliev, Rolf Marschalek, Larisa Fechina
Journal: Blood (2013)
C-reactive protein predicts recurrence after postoperative chemotherapy using S-1 in advanced gastric cancer patients
Authors: Takayuki Shimizu, Mitsuru Ishizuka, Takao Arakawa, Takashi Suzuki, Kazuma Tago, Hiroyuki Hachiya, Yasuhiro Harada, Kyunghwa Park, Takayuki Shiraki, Yuhki Sakuraoka, Shozo Mori, Akihito Abe, Yukihiro Iso, Kazutoshi Takagi, Taku Aoki, Keiichi Kubota
Journal: Annals of Oncology (2019)
Coversin Blocked in Vitro Hemolysis in an Eculizumab-Resistant PNH Patient with the C5 Polymorphism (c.2654G&gt;A)
Authors: Yasutaka Ueda, Makiko Osato, Wynne Weston-Davies, Miles A Nunn, Satoru Hayashi, Jun-Ichi Nishimura, Yuzuru Kanakura
Journal: Blood (2015)
ADAMTS13 Improving the Cell Engraftment Efficacy in Mouse Model of Bone Marrow Transplantation
Authors: Hideto Matsui, Masaaki Doi, Yasunori Matsunari, Maiko Takeda, Kenji Nishio, Midori Shima, Kenji Soejima, Fumiaki Banno, Masashi Akiyama, Koichi Kokame, Toshiyuki Miyata, Mitsuhiko Sugimoto
Journal: Blood (2012)
Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis
Authors: Massimo Breccia, Mario Tiribelli, Massimiliano Bonifacio, Alessia Tieghi, Nicola Polverelli, Micaela Bergamaschi, Francesco Cavazzini, Giuseppe Cimino, Mariella D'Adda, Monica Crugnola, Costanza Bosi, Marco Spinsanti, Matteo Molica, Angelo Fama, Alessandro Andriani, Elisa Cerqui, Antonio Lazzaro, Luigi Scaffidi, Fulvio Massaro, Roberto Latagliata, Francesca Celesti, Roberto massimo Lemoli, Renato Fanin, Domenico Russo, Franco Aversa, Antonio Cuneo, Michele Cavo, Nicola Vianelli, Giuliana Alimena, Francesca Palandri
Journal: Blood (2016)
Romiplostim (Nplate®) and Oprelvekin (Neumega®) Correct Thrombocytopenia in TAR Syndrome (Thrombocytopenia with Absent Radii)
Authors: Nicolas Gallastegui, Pamela B. Dudkiewicz, Wenche Jy, Lawrence L. Horstman, Yeon S. Ahn
Journal: Blood (2017)
Phototherapy and extracorporeal membrane oxygenation facilitate removal of carbon monoxide in rats
Authors: Luca Zazzeron, Anna Fischbach, Walfre Franco, William A. Farinelli, Fumito Ichinose, Donald B. Bloch, R. Rox Anderson, Warren M. Zapol
Journal: Science Translational Medicine (2019)

Extracorporeal blood phototherapy increases carbon monoxide elimination in rats and improves survival in animals with associated lung injury.
Elucidation of Additional Mutations By Next-Generation Sequencing Is of Clinical Significance in Patients with Rare MPNs and MDS/MPN Overlap Syndromes
Authors: Martin MJ Kirschner, Mirle Schemionek, Matthias Begemann, Susanne Isfort, Kristina Feldberg, Tim H. Brümmendorf, Steffen Koschmieder
Journal: Blood (2016)
Comparable Outcomes after Allogeneic Stem-Cell Transplantation with Intravenous Busulfan or Treosulfan-Based Reduced-Intensity and Reduced Toxicity Regimens in Acute Myeloid Leukemia. a Study on Behalf of the Acute Leukemia Working Party of EBMT
Authors: Avichai Shimoni, Myriam Labopin, Bipin N. Savani, Rose-Marie Hamladji, Dietrich W. Beelen, Ghulam J. Mufti, Gerard Socié, Jeremy Delage, Didier Blaise, Patrice Chevallier, Noel Milpied, Eric Deconinck, Mohamad Mohty, Arnon Nagler
Journal: Blood (2016)
Results of a Phase II Randomizing Intensified Rituximab Pre-Phase Followed By Standard FCR Vs Standard FCR in Previously Untreated Patients with Active B-Chronic Lymphocytic Leukemia (B-CLL). CLL2010FMP (for fit medically patients): A Study of the french Cooperative Group on CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d’Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS)
Authors: Stephane Lepretre, Rémy Letestu, Caroline Dartigeas, Hervé Maisonneuve, Therese Aurran, Pierre Feugier, Sophie de Guibert, Anne Bannos, Bernadette Corront, Veronique Leblond, Alain Delmer, Anne Laure Gagez, Valérie Rouillé, Sandrine Vaudaux, Florence Cymbalista, Guillaume Cartron, Emmanuelle Ferrant, Beatrice Mahe, Romain Guièze
Journal: Blood (2014)
Oncogenic Splicing of the Apoptosis-Stimulating Protein of p53-2 (ASPP2) Is an Initiating Step in Leukemogenesis Facilitating Acquisition of Structural Genomic Mutations
Authors: Kerstin Maria Kampa-Schittenhelm, Ulrike Mau-Holzmann, Charles Lopez, Marcus M. Schittenhelm
Journal: Blood (2016)
Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study
Authors: Maria Elisa Mancuso, Kathelijn Fischer, Elena Santagostino, Johannes Oldenburg, Helen Platokouki, Christoph Königs, Carmen Escuriola, Georges-Etienne Rivard, Ana Cid, Manuel Carcao, Rolf Ljung, Pia Petrini, Anne Rafowicz, Carmen Altisent, Gili Kenet, Raina Liesner, Karin Kurnik, Christel Van Geet, Teresa Alvarez-Roman, Tin Tin Yee, Guenter Auerswald, Rosario Perez-Garrido, Beatrice Nolan, Hervé Chambost, Anne Makipernaa, Angelo Claudio Molinari, Angela Thomas, Elizabeth Chalmers, Mike Williams, Rainer Kobelt, Marijke Van den Berg
Journal: Blood (2016)
Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study
Authors: Andrea Kuendgen, Michael Lauseker, Alan F. List, Pierre Fenaux, Aristoteles Giagounidis, Nancy Brandenburg, Jay Backstrom, Axel Glasmacher, Joerg Hasford, Ulrich Germing
Journal: Blood (2011)
Arsenic Trioxide Is a Well Tolerated Consolidation Regimen in Children with Newly Diagnosed Acute Promyelocytic Leukemia; Toxicity Results of the Children’s Oncology Group AAML0631 Trial
Authors: Matthew A. Kutny, Todd A. Alonzo, Robert B. Gerbing, Yi-Cheng Wang, Cecilia Fu, Soheil Meshinchi, Alan S. Gamis, James H. Feusner, John Gregory
Journal: Blood (2014)
Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged &lt; 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis
Authors: Pierre Fenaux, Aristoteles Giagounidis, Alan F. List, Stephen D. Nimer, Eva Hellström-Lindberg, Bayard L. Powell, Xujie Yu, Barry Skikne, Jamile M. Shammo, Consuelo del Cañizo
Journal: Blood (2011)
Enhanced Allogeneic Engraftment Achieved Via Prenatal Tolerance Induction and Postnatal Anti-CD45 Immunotoxin Conditioned Hematopoietic Cell Transplantation
Authors: Patrick E. McGovern, Agnieszka Czechowicz, Ali Mejaddam, John D. Stratigis, Haiying Li, John Urwin, Lauren E. McClain, Philip W. Zoltick, Alan W. Flake, William H. Peranteau
Journal: Blood (2016)
PKC Pathways Mediate BCR-ABL-Independent Imatinib Resistance in Chronic Myeloid Leukemia
Authors: Leyuan Ma, Yi Shan, Robert Bai, Liting Xue, Christopher A. Eide, Jianhong Ou, Lihua J. Zhu, Lloyd Hutchinson, Jan Cerny, H. Jean Khoury, Zhi Sheng, Brian J. Druker, Shaoguang Li, Michael Green
Journal: Blood (2014)
Expression of monocyte chemoattractant protein, CCL2/MCP-1, regulates bone marrow metastatic properties of breast cancer cell line
Authors: Munehisa Takahashi, Mutsuo Furihata, Hiroshi Miyazaki, Morihiro Watanabe, Tomoko Okada
Journal: Cancer Research (2008)

5388  [Purpose] To understand the mechanisms underlying bone marrow metastasis, we have established the highly bone marrow metastatic breast cancer cell line, 4T1E/M3 (E/M3). When injected intravenously or subcutaneously to mice, E/M3 cells showed higher metastatic activity to bone marrow. In vitro, they showed slightly higher proliferation, stronger adhesion to plastic and to bone marrow-derived endothelial cells and higher expression of ICAM-1 and β2 integrin compared to parent cells. Further, they had greater anchorage-independent growth, and higher migration activity. Using this model, we compared gene expression between parent and E/M3 cells and found that the expression of CCL2 was remarkably suppressed in E/M3 compared to parent cells. To clarify the role of CCL2, we examined the properties of CCL2-overexpressing E/M3 cells.  [Methods] DNA microarray and RT-qPCR were used for gene analysis. CCL2-overexpressing E/M3 cells were established by transfecting CCL2 cDNA into E/M3 cells. Using these cells, we carried out in vivo (survival, metastasis) and in vitro studies (proliferation, wound-healing, and colony formation assays). Expression of surface adhesion molecules was analyzed by fluorescence activated cell sorter.  [Results] Gene analysis revealed that expression of CCL2 was remarkably suppressed among other chemokines in E/M3 compared to parent cells. By the histological analysis, CCL2-overexpressing E/M3 showed lower bone marrow metastatic activity than control cells. Moreover, the survival of mice intravenously injected with CCL2-overexpressing E/M3 was significantly longer than the mice receiving control cells. Furthermore, we found that CCL2-overexpressing E/M3 cells showed reduced cell migration and decreased anchorage-independent proliferation. The expression of ICAM-1, which was increased in E/M3 and involved in the cell motility and anchorage-independent growth of these cells, was downregulated in CCL2-overexpressing E/M3. These results suggest that CCL2 is one of the key molecules that control breast cancer metastasis through the regulation of the expression of ICAM-1 in our model.
N-Cadherin and Cadherin-11 Play Vital Roles in the Cell-Cell Contact between Hematopoietic Progenitor Cells and Mesenchymal Stromal Cells.
Authors: Wolfgang Wagner, Frederik Wein, Anke Diehlmann, Rainer Saffrich, Patrick Wuchter, Christoph Roderburg, Volker Eckstein, Anthony D. Ho
Journal: Blood (2007)
The Role of Periodic Limb Movement in Sleep of Patients with Sickle Cell Disease.
Authors: Marina Roizenblatt, Suely S Roizenblatt, Perla Vicari, Martha M A S Arruda, Felipe Chediek, Fabiano Abrantes, Antonio V Morais, Sergio Tufik, Maria Stella Figueiredo
Journal: Blood (2009)
Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Authors: Terry J. Fry, Maryalice Stetler-Stevenson, Nirali N Shah, Constance M. Yuan, Bonnie Yates, Cindy Delbrook, Ling Zhang, Daniel W. Lee, David Stroncek, Crystal L. Mackall
Journal: Blood (2015)
Nucleophosmin Gene Mutations Exhibit High Spontaneous Apoptosis and Favorable Prognosis in Acute Myeloid Leukemia.
Authors: Giovanni Del Poeta, Emanuele Ammatuna, Serena Zaza, Francesco Buccisano, Tiziana Ottone, Maria Ilaria Del Principe, Serena Lavorgna, Gianfranco Catalano, Luca Maurillo, Fabrizio Luciano, Paolo de Fabritiis, Adriano Venditti, Sergio Amadori, Francesco Lo Coco
Journal: Blood (2007)